| Issue |
Med Sci (Paris)
Volume 31, Number 4, Avril 2015
|
|
|---|---|---|
| Page(s) | 447 - 449 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/20153104020 | |
| Published online | 08 May 2015 | |
23andMe ou comment (très bien) valoriser ses clients
Chroniques génomiques
23andMe: how to make (a lot of) money out of your customers
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS,Espace éthique méditerranéen, hôpital d’adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France
*
bertrand.jordan@univ-amu.fr
**
brjordan@orange.fr
Abstract
The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for targeted drug development. This may be a useful strategy, but it raises a number of questions concerning the privacy of the company’s customers and also of adequate compensation when they become valuable currency.
© 2015 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.